Entrepreneur, bioscientist and biomathematician with three decades' experience in biopharma and artificial intelligence. Strategic R&D advisory and interim management for the biopharma sector.
Our mission: Bridging the Epistemic Gap in Biopharma R&D
The Biopharma R&D sector is facing a productivity paradox. Despite record investments in AI and high-throughput technologies, clinical success rates continue to decline. At the heart of this crisis lies the Epistemic Gap: a fundamental disconnect between theoretical laboratory models and the complex biological reality of human patients.
Engineering Probability of Success (PoS)
Jobst Landgrebe Consulting provides a dual-engine strategy to restore R&D efficiency: By integrating Biomathematical Rigour with Human-Centric Validation (Organoids), we help research leaders move beyond speculative “black-box” models. Our “Smart Selection” approach identifies “false positive” targets early, ensuring that only assets with the highest Probability of Success (PoS) proceed to the clinic.
Modular Strategic Support
From Methodological Audits to solving technical deadlocks in “undruggable” targets, we provide modular interventions designed to increase capital efficiency. Whether through interim management, talent scouting, or scientific due diligence, our focus remains constant: closing the gap between theory and human therapeutic success.
Whitepaper - Target re-utilisation at the C-terminus
Many biopharmaceuticals are currently re-targeting existing mAB targets in the extracellular space (ligands and receptors) with orally available molecules - a medically viable option that unfortunately has recently become crowded thus reducing commercial opportunities. How can we overcome this? My newest whitepaper shows two examples of extracellular receptor targeting and then discuss a third approach, the targeting of intracellular (C-terminal) receptor interaction domains to block down-stream signalling, which offers new possibilities in a less crowded space.
